Novocure Reports Second Quarter 2026 Financial Results
Novocure delivered Q2 revenue of $183.6 million, up 16% year-over-year, driven by record active patient growth which reached 5,128 globally. The company achieved positive Adjusted EBITDA of $10.8 million and raised full-year 2026 revenue guidance to $710M-$725M with Adjusted EBITDA expected to reach breakeven or better.
Key figures
- Revenue
- 183600000
- Guidance
- FY26 revenue $710M-$725M (raised from $690M-$710M); Adj EBITDA $0M-$15M (raised from $(15)M-$0M)
- Adj ebitda
- 10800000
- Gross margin
- 78%
- Cash position
- 440600000
- Optune lua revenue
- 5400000
- Optune pax revenue
- 1600000
- Active patients total
- 5128
- Optune pax active patients
- 285
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.